Altre lingue CEL-SCI Corporation

Azioni

CVM

US1508376076

Mercato chiuso - Nyse Altri mercati azionari 22:00:00 15/07/2024			Variaz. 5gg	Var. 1 gen.
1,31 ^USD	+2,34%		+6,50%	-51,84%

08/07	CEL-SCI Corporation nomina Robert Watson Presidente del Consiglio di Amministrazione	CI
20/06	CEL-SCI Corporation presenta i dati sul cancro della testa e del collo al Congresso Annuale Iddst di Budapest: Rischio di morte dimezzato per i pazienti trattati con Multikine nella popolazione target	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Cel-Sci Appoints Robert Watson Board's Chair	08/07
CEL-SCI Appoints Robert Watson as Chairperson of the Board	08/07
CEL-SCI Corporation Appoints Robert Watson as Chairperson of the Board	08/07
CEL-SCI Corporation(NYSEAM:CVM) dropped from Russell Microcap Value Index	01/07
CEL-SCI Corporation(NYSEAM:CVM) dropped from Russell 3000E Value Index	01/07
CEL-SCI Corporation Presents Head & Neck Cancer Data At Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated with Multikine in the Target Population	20/06
CEL-SCI Presents Head and Neck Cancer Data at Iddst Annual Congress in Budapest, Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population	19/06
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population	18/06
CEL-SCI Corporation (von First Berlin Equity Research GmbH...	11/06
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor	06/06
Cel-Sci: Fiscal Q2 Earnings Snapshot	16/05
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results	16/05
CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	15/05
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head and Neck Cancer	09/05
Cel-Sci Gets US FDA Clearance to Proceed With Confirmatory Study for Cancer Drug Multikine	08/05
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer	08/05
CEL-SCI Corporation Announces Significantly Positive Outcome from its Recent Meeting with U.S. Food and Drug Administration Regarding Path to Approval for its First-Line Investigational Cancer Immunotherapy Multikine	08/05
CEL-SCI Corporation Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer	08/05
CEL-SCI Appoints Mario Gobbo to Its Board of Directors	23/04
CEL-SCI Corporation Appoints Mario Gobbo as Board of Directors	23/04

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue CEL-SCI Corporation

Azioni

CVM

US1508376076

Altre lingue

Filtri